Boston Scientific Corporation $BSX Position Reduced by Associated Banc Corp

Associated Banc Corp reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 372,060 shares of the medical equipment provider’s stock after selling 2,821 shares during the period. Boston Scientific comprises approximately 1.1% of Associated Banc Corp’s holdings, making the stock its 22nd biggest position. Associated Banc Corp’s holdings in Boston Scientific were worth $39,963,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the stock. 1248 Management LLC bought a new stake in Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the 1st quarter worth approximately $27,000. Sound Income Strategies LLC increased its holdings in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the last quarter. Princeton Global Asset Management LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific during the second quarter worth $37,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.1%

Shares of Boston Scientific stock opened at $97.97 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The business’s fifty day moving average price is $98.93 and its two-hundred day moving average price is $102.31. The company has a market capitalization of $145.23 billion, a P/E ratio of 52.39, a PEG ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period last year, the company earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of research reports. Robert W. Baird increased their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Truist Financial boosted their price objective on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Wells Fargo & Company raised their target price on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. BTIG Research restated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $123.77.

Insider Transactions at Boston Scientific

In other news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 175,782 shares of company stock worth $17,742,314 over the last 90 days. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.